Histogen Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic.
Latest period: Q3 2023.
-
Location
-
San Diego, CA
-
Fiscal year end
-
31 December
-
Latest financial report
-
09 Nov 2023
Shareable Research Card
Histogen Inc. Financial Facts
Histogen Inc. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
- Context
- Latest metrics period: Q3 2023
- Latest reported value
- Operating Margin -63447%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2023
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2023.
- Most recent SEC facts end date on this page: 09 Nov 2023.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Histogen Inc.
New fact period available
Latest financial period: Q3 2023. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
09 Nov 2023
Page type
Company facts
Latest period
Q3 2023
SEC-backed company facts were refreshed from filings filed on 09 Nov 2023.
Benchmark Context
How Operating Margin compares
Operating Margin is up about 22029% versus the comparable prior period.
Compared with
Compared with Histogen Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Operating Margin already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2023.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Quick Takeaways
- Histogen Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q3 2023.
- Headline metric: Operating Margin -63447%.
What Changed
- Operating Margin YoY change: +22029%.
- Most recent SEC facts end date: 09 Nov 2023.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Source Evidence
Based on latest 10-Q/10-K
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
See Original Filing
Latest SEC snapshot (2023-11-09) highlights Operating Margin -63447.4%, Current Ratio 4.05x, and Quick Ratio 3.39x.
Compare This Company Through SEC-backed Metrics
Use these links to compare Histogen Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: -99%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
41.3/100
Caution
Confidence low
Financial Health
- Current Ratio
- 4.05x
- Quick Ratio
- 3.39x
- Debt to Equity
- 0.45x
Watchpoints
Operating Margin and Revenues YoY
Profitability
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Operating Margin
|
-63447%
|
+22029%
|
Q3 2023
|
|
%
|
Growth
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Revenues YoY
|
-99%
|
|
Q3 2023
|
|
%
|
Share Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Entity Common Stock, Shares Outstanding
|
4,271,759
|
0%
|
Q3 2023
|
Q3 2023
|
shares
|
|
Common Stock, Shares, Outstanding
|
4,271,759
|
0%
|
Q3 2023
|
Q3 2023
|
shares
|
|
Common Stock, Value, Issued
|
$5,000
|
0%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Weighted Average Number of Shares Outstanding, Basic
|
4,271,759
|
+20%
|
Q3 2023
|
Q3 2023
|
shares
|
|
Weighted Average Number of Shares Outstanding, Diluted
|
4,271,759
|
+20%
|
Q3 2023
|
Q3 2023
|
shares
|
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Accounts Payable, Current
|
$386,000
|
-31%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Accounts Receivable, after Allowance for Credit Loss, Current
|
$0
|
-100%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Accrued Liabilities, Current
|
$943,000
|
+59%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Assets
|
$5,817,000
|
-74%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Assets, Current
|
$5,455,000
|
-67%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Cash and Cash Equivalents, at Carrying Value
|
$4,573,000
|
-69%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
|
$4,873,000
|
-67%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Common Stock, Par or Stated Value Per Share
|
0
|
0%
|
Q3 2023
|
Q3 2023
|
USD/shares
|
|
Common Stock, Shares Authorized
|
200,000,000
|
0%
|
Q3 2023
|
Q3 2023
|
shares
|
|
Common Stock, Shares, Issued
|
4,271,759
|
0%
|
Q3 2023
|
Q3 2023
|
shares
|
|
Earnings Per Share, Basic
|
-3
|
+11%
|
Q3 2023
|
Q3 2023
|
USD/shares
|
|
Earnings Per Share, Diluted
|
-3
|
+11%
|
Q3 2023
|
Q3 2023
|
USD/shares
|
|
Employee-related Liabilities, Current
|
$787,000
|
+443%
|
Q3 2023
|
Q3 2023
|
USD
|
|
General and Administrative Expense
|
$8,796,000
|
-2.7%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Income Tax Expense (Benefit)
|
$0
|
|
Q3 2023
|
Q3 2023
|
USD
|
|
Liabilities
|
$1,413,000
|
-76%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Liabilities and Equity
|
$5,817,000
|
-74%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Liabilities, Current
|
$1,348,000
|
-3.6%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Operating Income (Loss)
|
$12,055,000
|
-12%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Other Assets, Current
|
$40,000
|
-57%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Other Assets, Noncurrent
|
$362,000
|
-43%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Preferred Stock, Par or Stated Value Per Share
|
0
|
0%
|
Q3 2023
|
Q3 2023
|
USD/shares
|
|
Preferred Stock, Shares Authorized
|
10,000,000
|
0%
|
Q3 2023
|
Q3 2023
|
shares
|
|
Preferred Stock, Shares Issued
|
0
|
|
Q3 2023
|
Q3 2023
|
shares
|
|
Preferred Stock, Shares Outstanding
|
0
|
|
Q3 2023
|
Q3 2023
|
shares
|
|
Property, Plant and Equipment, Net
|
$0
|
-100%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Research and Development Expense
|
$3,278,000
|
-41%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Retained Earnings (Accumulated Deficit)
|
$97,686,000
|
-15%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Revenue from Contract with Customer, Excluding Assessed Tax
|
$19,000
|
-99%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Share-based Payment Arrangement, Expense
|
$534,000
|
+19%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Stockholders' Equity Attributable to Parent
|
$5,436,000
|
-69%
|
Q3 2023
|
Q3 2023
|
USD
|
|
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
|
$4,404,000
|
-73%
|
Q3 2023
|
Q3 2023
|
USD
|
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric |
Weight |
V1 threshold |
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Explore related SEC datasets